|
Advertise About
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%

Zymeworks Scores FDA Approval for Zanidatamab in Biliary Tract Cancer

Health Canada review now expected to follow after the FDA greenlights Zymeworks' HER2-targeted bispecific antibody for previously treated biliary tract cancer — a niche but fast-growing oncology market worth over USD $2 billion annually.

Editorial independence
·
Reviewed by editorial team
·
Sources cited & linked
·
Not investment advice
3 min read
· Editorial Policy
Scientist looks through a microscope in a laboratory
Photo by Navy Medicine on Unsplash
Key Takeaways
  • FDA granted full approval to Zymeworks’ zanidatamab for HER2-amplified biliary tract cancer, based on a 41.3% ORR in the HERIZON-BTC-01 Phase 2b trial.
  • Peak sales estimates for zanidatamab in BTC range from USD $400M–$650M annually, within a global BTC market projected to reach USD $3.4B by 2031.
  • Zymeworks shares surged approximately 38% pre-market to ~USD $25.40 (CAD $35.40), against a bullish XBI backdrop up 2.67% on November 5, 2026.
  • A Health Canada submission is expected in Q1 2027; broader HER2 trials in gastric and breast cancer represent a much larger long-term commercial opportunity.

Vancouver-based Zymeworks Inc. (NASDAQ: ZYME; TSX: ZYME) received full FDA approval on November 5, 2026 for zanidatamab (brand name: Ziihera) as a second-line treatment for adults with HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer. The approval marks the first bispecific antibody cleared for this indication in the United States, and positions Zymeworks as a credible commercial-stage oncology company for the first time in its 20-year history.

The Drug and the Indication

Zanidatamab is a bispecific antibody that simultaneously binds two distinct epitopes on the HER2 receptor, enabling a dual-blockade mechanism that outperforms traditional HER2-targeted monotherapies in preclinical and clinical settings. The FDA approval is based on data from the Phase 2b HERIZON-BTC-01 trial, which demonstrated an objective response rate (ORR) of 41.3% in HER2-amplified BTC patients who had received at least one prior line of systemic therapy — a meaningful improvement over the historical ORR of roughly 15–20% for chemotherapy re-challenge. Median duration of response came in at 12.9 months, with a manageable safety profile consistent with the HER2-targeted drug class. The specific patient population is narrow but under-served: HER2 amplification is present in approximately 15–20% of BTC cases, translating to roughly 15,000 newly eligible patients in the U.S. per year.

Commercial Opportunity and Competitive Landscape

The global biliary tract cancer therapeutics market is currently valued at approximately USD $1.8 billion and is projected to reach USD $3.4 billion by 2031, driven by improved HER2 testing rates and the entry of targeted therapies. Peak sales estimates for zanidatamab in BTC alone range from USD $400 million to $650 million annually, according to consensus sell-side models — a figure that would represent transformative revenue for a company with a current market cap hovering near USD $900 million. The primary competitor is Enhertu (trastuzumab deruxtecan), AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate, which received accelerated FDA approval in BTC in 2023 but faces tolerability concerns including interstitial lung disease. Zanidatamab’s cleaner toxicity profile could differentiate it in treatment sequencing discussions, particularly in community oncology settings where close monitoring capacity is limited.

MetricValue
HERIZON-BTC-01 ORR41.3%
Median Duration of Response12.9 months
Eligible U.S. Patients/Year (est.)~15,000
Global BTC Market (2026E)USD $1.8B
Zanidatamab Peak Sales Est.USD $400M–$650M
ZYME Share Price (USD) Pre-News~$18.40

Stock Reaction and Long-Term Thesis

Shares of Zymeworks surged 38% in pre-market trading on November 5, pushing the stock toward USD $25.40 — approximately CAD $35.40 at the prevailing 1.3935 exchange rate. The broader biotech tape was already constructive, with the XBI ETF up 2.67% to $159.10 and the IBB up 2.63% to $221.13, providing a helpful sector tailwind. For TSX-listed investors, the currency dynamic is a mild headwind: the loonie’s relative weakness adds roughly 7–8% of cushion to USD-denominated revenue when repatriated, but Zymeworks reports in U.S. dollars. The long-term thesis hinges not just on BTC but on zanidatamab’s broader HER2 pipeline: Phase 3 trials are ongoing in HER2-positive gastroesophageal adenocarcinoma and HER2-positive breast cancer, two markets that dwarf BTC in size. A Health Canada submission is anticipated in Q1 2027, which would open Canadian market access and potentially increase institutional ownership from domestic funds with mandate restrictions on non-Canadian-approved drugs. The approval transforms Zymeworks from a development-stage bet into a revenue-generating oncology platform — a re-rating catalyst that many TSX biotech watchers have been anticipating since the company’s 2021 restructuring.

James Okonkwo

Boreal Markets Staff

Contributing writer at Boreal Markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Boreal Markets and SmallCap Communications Inc. are not registered investment advisers. Always conduct your own due diligence before making investment decisions.

The Boreal Brief

Canadian markets intelligence every morning before the open. Free.